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Abstract
Purpose We have previously reported on the prognostic importance of the calpain family of proteins in ovarian cancer, 
especially calpain-2. Spleen tyrosine kinase (Syk) phosphorylates a variety of cytoskeletal proteins with studies suggesting 
potential interactions between Syk and conventional calpains. Microtubule-associated protein 4 (MAP4) has been reported 
to be regulated by Syk.
Methods The current study assessed Syk and MAP4 protein expression, by immunohistochemistry on a tissue microarray 
comprised of cores from primary ovarian carcinomas (n = 575), to evaluate associations with patient clinical outcomes and 
other clinicopathological factors and sought to determine whether there were any correlations between the expression of 
Syk, MAP4 and the calpain system.
Results MAP4 expression was significantly associated with ovarian cancer histological subtype (P < 0.001), stage (P = 0.001), 
grade (P < 0.001) and residual tumour (P = 0.005). Despite this finding, we found no significant association existing between 
MAP4 expression and overall survival. Syk expression was also found significantly associated with histological subtype 
(P < 0.001). Syk seems to play a contradictory role with respect to tumour progression: low cytoplasmic Syk expression was 
significantly associated with low stage (P = 0.013), and low nuclear Syk expression with chemo-resistance in patients treated 
with taxane-containing therapy (P = 0.006). Interestingly, despite the lack of association in the whole cohort, high nuclear 
Syk expression was significantly associated with better overall survival in certain subgroups (P = 0.001).
Conclusions The current study indicates a lack of correlation between calpain-2 expression and Syk and MAP4. Syk, MAP4 
and calpain-1 appeared to significantly correlate with each other in the whole cohort, with calpain-1 being more highly 
associated with MAP4 and Syk in mucinous carcinomas. Overall, the current results suggest that Syk, MAP4, and calpain-1 
expression are correlated with each other and these proteins may be involved in early stages of tumour spread.
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Abbreviations
MAP  Microtubule-associated protein
Syk  Spleen tyrosine kinase
Syk-c  Cytoplasmic Syk
Syk-n  Nuclear Syk
Introduction and aims
The calpain system has been confirmed to play an important 
role in influencing ovarian cancer patient outcomes with the 
adverse association between high calpain-2 expression and 
worse overall survival in ovarian cancer (Storr et al. 2012) 
being recently verified, and with calpain-4 and calpastatin 
expression also being found to be associated with overall 
survival (Zhang et al. 2018). However, the mechanisms 
whereby the calpain system exerts it important effects in 
ovarian cancer progression remain to be fully elucidated.
Spleen tyrosine kinase (Syk), a cytoplasmic non-
receptor tyrosine kinase (Baldock et al. 2000), is widely 
expressed in a variety of hematopoietic cells (Singh et al. 
2012; Krisenko and Geahlen 2015) and has been detected 
in osteoclasts, normal and tumourigenic mammary epi-
thelial cells, melanocytes, human nasal fibroblasts, 
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hepatocytes, neuronal cells and vascular endothelial cells 
suggesting that Syk has a general physiological function 
in a wide variety of non-hematopoietic cells (Coopman 
and Mueller 2006; Yanagi et al. 2001; Singh et al. 2012). 
Syk has been reported as a pro-survival factor in many 
hematopoietic malignancies (Krisenko and Geahlen 2015) 
and some epithelial original tumours (Geahlen 2014); 
however, it has also been hypothesised to have a tumour 
suppressor role in cancers of non-immune cells (Moroni 
et al. 2004; Coopman et al. 2000; Coopman and Mueller 
2006; Krisenko and Geahlen 2015). A decrease in Syk 
expression in highly malignant and invasive tumour cells 
has been observed in a range of cancers including lung 
(Chuanliang et al. 2016) and hepatocellular cancer (Hong 
et al. 2012; Yuan et al. 2006). Expression has been found 
negatively associated with cell proliferation and anchor-
age-independent growth; moreover, negative associations 
have also been detected between Syk and cell migration, 
lymphovascular invasion, microvessel density and/or 
metastasis formation in cancers (Ogane et al. 2009; Fei 
et al. 2013; Nakashima et al. 2006; Coopman and Mueller 
2006; Peng et al. 2013; Chuanliang et al. 2016).
Data in the literature have suggested potential interac-
tions between Syk and the calpain system. A C-terminal 
fragment (40–45 kDa) of Syk was generated by calpain 
cleavage of human recombinant Syk (Baldock et al. 2000) 
and calpain inhibitors have been shown to significantly 
increase the presence of full-length Syk (72 kDa) on cell 
membrane (Gonscherowski et al. 2006) suggesting that 
Syk is a calpain substrate. An additional study suggests 
that Syk appears upstream of calpains rather than being a 
calpain substrate thus the effect of Syk on calpain activ-
ity seems contradictory and may depend on the cellular 
context (Fei et al. 2013).
A recent study suggested an association between Syk 
and MAP4 in ovarian cancer cells (Yu et al. 2015). MAP4 
is the predominant human non-tubulin component of 
microtubule-associated protein in non-neuronal tissues 
(Orr et al. 2003). Syk-mediated tyrosine phosphorylation 
of MAP1B and MAP4 can induce paclitaxel resistance 
via reducing microtubule stabilisation (Yu et al. 2015; 
Krisenko et al. 2014; Wei and Birrer 2015).
As mentioned above, results from previous ovarian can-
cer studies confirm that the calpain system is associated 
with patient overall survival, particularly calpain-2 expres-
sion. In addition, calpain-1 expression showed significant 
association with tumour stage suggesting that calpain-1 
might mediate tumour spread (Zhang et al. 2018). The 
current study sought to assess Syk and MAP4 expression 
in a large cohort of ovarian cancer specimens, to evalu-
ate associations with patient clinical outcomes and other 
clinicopathological factors and additionally sought to 
determine whether there were any correlations between 
the expression of Syk, MAP4 and the calpain system.
Materials and methods
Clinical samples
The ovarian tissue microarray was composed of tumour 
cores from 575 ovarian cancer cases, with 448 chemo-naïve 
Table 1  Clinicopathologic variables of the patient cohort
Variable Number of 
patients
Percentage (%)
Age
 ≤ 62 295 52.4
 > 62 268 47.6
Histological subtypes
 HGSC 337 59.7
 Mucinous carcinoma 60 10.6
 Endometrioid carcinoma 68 12.1
 CCC 53 9.4
 LGSC 30 5.3
 SBOT 15 2.7
Grade
 1 48 8.5
 2 90 16.0
 3 425 75.5
Stage
 I 203 36.7
 II 64 11.6
 III 245 44.3
 IV 41 7.4
Residual disease
 No residual tumour 311 62.2
 Residual tumour (< 2 cm) 58 11.6
 Residual tumour (> 2 cm) 131 26.2
Adjuvant therapy
 Pt-based chemotherapy 357 63.3
 Non-platinum-based chemotherapy 6 1.1
 No chemotherapy 80 14.2
 Information not available 121 21.5
Response to chemotherapy
 Refractory and resistance 66 17.7
 Sensitivity 307 82.3
Progression status
 No recurrence 137 32.9
 Recurred 280 67.1
Survival status
 Living 234 42.0
 Deceased 323 58.0
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samples, as described previously (Zhang et  al. 2018). 
The clinicopathological variables of the cohort are listed 
in Table 1. Patients were diagnosed with ovarian cancer 
and received treatment at Nottingham University Hospi-
tals between 1991 and 2011. The majority of the patients 
(n = 357) received platinum-based chemotherapy among 
which 168 patients were treated with chemotherapy con-
taining taxanes. Progression-free survival was defined as the 
length of time between start of treatment and clinical identi-
fication of recurrence. Data on resistance to chemotherapy 
was recorded, classified by the Gynaecologic Oncology 
Group (GOG) as either refractory (not responding to chemo-
therapy), resistant (an initial response to chemotherapy with 
recurrence within 6 months) or sensitive (when there was 
either no recurrence or recurred after 6 months). Ethical 
approval was obtained from Derbyshire Ethics Committee 
(07/H0401/156). This study is reported in accordance with 
REMARK (reporting recommendations for tumour marker 
prognostic studies) criteria (McShane et al. 2005).
Tissue microarray, immunohistochemistry 
and interpretation
Protein expression was investigated using sections taken 
from the same tissue microarray blocks that were used in 
the previous study, that assessed calpain system protein 
expression, i.e., calpain-1, -2, -4 and calpastatin (Zhang 
et al. 2018). For the majority of the cases, a single tissue 
core was used for each patient. Fresh sections (4 µm) were 
cut from each block and placed on coated glass slides for 
the immunohistochemical assessment of protein expression.
Immunohistochemistry was performed as described 
previously (Storr et al. 2012; Zhang et al. 2018). Primary 
antibodies were diluted in Bond Primary Antibody Diluent 
(Leica, Denmark), MAP4 antibody (1:400; Bethyl Laborato-
ries, INC; A301-489A) and Mouse monoclonal anti-human 
Syk antibody (4D10.1) (1:1600; Thermo Fisher Scientific; 
MA5-13087), and applied to the tissue overnight at 4 °C. 
The specificity of these antibodies was initially confirmed by 
Western blotting before conducting IHC (Fig. S1). Negative 
controls omitted primary antibody. Slides were scanned and 
cytoplasmic staining intensity semi-quantitatively assessed, 
for Syk and MAP4, using an immunohistochemical H-score 
as described previously (Storr et al. 2012; Zhang et al. 2018). 
Nuclear staining intensity was also scored for Syk, and the 
percentage of stained nuclei recorded. Greater than 25% of 
the slides were examined by a second independent asses-
sor blinded to scores and clinicopathologic criteria. Single 
measure intraclass correlation coefficient (ICC) analysis was 
used to determine the level of agreement between independ-
ent scorers. The single measure ICCs between scores were 
0.925, 0.833 and 0.887 for anti-Syk antibody cytoplasmic 
and nuclear-stained samples, and anti-MAP4 antibody-
stained samples, respectively. A non-biased cut-point of 
the immunohistochemical scores, to dichotomise data, was 
determined using X-tile software using patient OS (Camp 
et al. 2004; Storr et al. 2012).
Statistical analysis
The relationships between categorised protein expression 
and clinicopathologic factors were examined using Pearson’s 
Chi-squared test of association (χ2) or Fisher’s exact test if a 
cell count was less than 5 in a 2 × 2 table. To assess the rela-
tionship between protein expression and survival outcomes, 
survival curves were generated using the Kaplan–Meier 
method and statistical significance determined by the Log-
rank test. Multivariate survival analysis was performed using 
a proportional hazards model by Cox regression analysis 
to estimate hazard ratios and 95% confidence intervals for 
overall survival. Spearman’s rank correlation coefficient 
(Spearman’s ρ) test was performed to assess the correlation 
between the expression levels of different proteins. The cor-
relation strength was interpreted as follows: Spearman ρ (rs) 
less than 0.16 is too weak to be meaningful, ranging from 
0.16 to 0.19 as very weak correlation; 0.20 to 0.39 as a weak 
correlation; 0.40 to 0.59 as a moderate correlation; 0.60 to 
0.79 as strong correlation and 0.80 or greater as very strong 
correlation (Divaris et al. 2012). Statistical analyses were 
carried out using SPSS 22.0 software. P values < 0.05 were 
considered statistically significant.
Results
Similar to reports by Zhang et al. (2009) and Fei et al. (2013) 
Syk was expressed in both the cytosol and nucleus. MAP4 
showed predominant staining in the cytoplasm of the ovar-
ian cancer cells with membranous staining apparent. Rep-
resentative staining patterns of weak, moderate, and strong 
staining intensity are shown in Fig. 1. Both Syk and MAP4 
showed granular/diffuse staining with heterogeneity between 
adjacent cancer cells. In addition to the staining of tumour 
cells, Syk and MAP4 staining was observed in areas of 
tumour-adjacent normal tissue; moreover, Syk staining was 
also observed in immune cells. The current study focused 
only on the staining of tumour cells.
The expression of Syk and MAP4 
and clinicopathological factors
High cytoplasmic Syk (Syk-c) expression was observed in 
374 (85%) out of 441 cases, and nuclear Syk (Syk-n) expres-
sion was observed in 329 (75%) cases (Syk-c cut-point: 
65; Syk-n cut-point: 12). Pearson’s Chi-squared test was 
 Journal of Cancer Research and Clinical Oncology
1 3
performed to evaluate the relationships with the expression 
of calpain-system proteins and with clinicopathologic char-
acteristics, with results shown in Table 2. HGSCs often dis-
played higher Syk expression in the cytoplasm and nucleus 
(Syk-c: χ2 = 58.835, df = 5, P = 2.115E−11 and Syk-n: 
χ2 = 29.874, df = 5, P = 0.000016, respectively). Low Syk-c 
expression was linked with lower stage (χ2 = 10.725, df = 3, 
P = 0.013), whilst low Syk-n expression significantly asso-
ciated with chemo-resistance in patient treated by therapy 
containing taxanes (χ2 = 7.582, df = 1, P = 0.006).
The above analysis was also conducted in chemotherapy-
naïve cases (n = 448) (data not shown). Significant asso-
ciations were found between Syk expression and ovarian 
cancer subtype (Syk-c: χ2 = 46.443, df = 5, P = 7.3773E−9; 
Syk-n: χ2 = 26.744, df = 5, P = 0.000064), stage (only Syk-
c: χ2 = 11.520, df = 3, P = 0.009), and tumour response to 
taxane-containing chemotherapy (only Syk-n: χ2 = 7.078, 
df = 1, P = 0.008).
High MAP4 expression was observed in 291 (66%) out of 
442 cases (cut-point: 152). Pearson’s Chi-squared test was 
performed to evaluate the associations of clinicopathologi-
cal factors with MAP4 expression (Table 3). HGSCs exhib-
ited significantly higher MAP4 expression (χ2 = 56.386, 
df = 5, P = 6.7681E−11). Low expression was significantly 
associated with lower stage (χ2 = 15.857, df = 3, P = 0.001) 
and lower grade (χ2 = 22.933, df = 2, P = 0.00001). A signifi-
cant association was detected between high MAP4 expres-
sion and the presence of residual tumour (χ2 = 10.426, df = 2, 
P = 0.005).
The above analysis was also conducted in chemother-
apy-naïve cases (n = 448). MAP4 expression was sig-
nificantly associated with subtype (χ2 = 45.528, df = 5, 
P = 1.1332E−8), grade (χ2 = 14.209, df = 2, P = 0.001), stage 
(χ2 = 15.050, df = 3, P = 0.002), residual disease (χ2 = 9.965, 
df = 1, P = 0.007) and tumour response to taxane-containing 
chemotherapy (χ2 = 4.596, df = 1, P = 0.032; high MAP4 
expression associated with chemo-sensitisation).
Patients were then grouped according to whether they had 
an organ-confined tumour (i.e., group 1: stage 1 and group 2: 
stage 2–4) or according to whether they had distant metas-
tasis (i.e., group 1: stage 1–3 and group 2: stage 4). Higher 
significance was observed for Syk and MAP4 expression, 
regarding tumour spread, when grouping patients into two 
broader categories by organ-confined status than grouping 
by FIGO staging classifications (Table S1). Low Syk-c, low 
Syk-n and low MAP4 showed significant association with 
organ-confined status of tumour (Syk-c: χ2 = 9.975, df = 1, 
P = 0.002; Syk-n: χ2 = 4.169, df = 1, P = 0.041; and MAP4: 
Fig. 1  Representative photo-
micrographs of Syk and MAP4 
expression in ovarian carcinoma 
cells. Expression levels, includ-
ing low (left), medium (middle) 
and high (right) staining, of Syk 
and MAP4 at × 10 magnifica-
tion with × 20 magnification 
inset panel. Negative controls 
omitted primary antibody. Scale 
bar represents 100 µm
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χ2 = 15.402, df = 1, P = 0.000087), whereas no significant 
association was detected between protein expression and 
cancer distant metastasis. In chemotherapy-naïve cases 
(n = 448), low Syk-c, low Syk-n and low MAP4 also showed 
significant association with organ-confined status of tumour 
(Syk-c: χ2 = 10.551, df = 1, P = 0.001; Syk-n: χ2 = 5.041, 
df = 1, P = 0.025; MAP4: χ2 = 14.322, df = 1, P = 0.000154). 
Such findings suggest that, similar to previous observations 
with calpain-1, MAP4 and Syk expression may be more 
related to early events of tumour spread.
The expression of Syk and MAP4 and clinical 
outcomes
The expression of Syk-c, -n or MAP4 had no significant 
associations with overall survival (Fig. 2a, c and e) or pro-
gression-free survival (Fig. 2b, d and f). Further analysis 
was conducted to investigate the prognostic significance 
of Syk and MAP4 in the individual subgroups defined by 
clinicopathologic variables. P values of log-rank tests for 
overall survival in association with each protein expression 
are listed in Table S2. High Syk-n expression indicated a 
better overall survival among platinum-resistant patients 
(P = 0.001, Fig. 3a), patients with tumours confined to the 
ovaries (stage 1 ovarian cancer) (P = 0.001, Fig. 3b) and 
patients with no residual disease (P = 0.001) (Fig. 3c).
Table 2  Association between Syk expression and clinicopathological criteria
HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma, CCC clear-cell carcinoma, SBOT serous borderline ovarian tumour
*Expected count less than 5. Significant P values are indicated by bold font
Variable Syk-c expression Syk-n expression
Low High P value Low High P value
Age
 ≤ 62 30 (6.8%) 184 (41.8%) 0.492 51 (11.6%) 163 (37.0%) 0.447
 > 62 37 (8.4%) 189 (43.0%) 61 (13.9%) 65 (37.5%)
Histological subtypes
 HGSC 25 (5.7%) 247 (56.0%) 2.115E−11* 57 (12.9%) 215 (48.8%) 1.6E−5*
 Mucinous 9 (2.0%) 34 (7.7%) 10 (2.3%) 33 (7.5%)
 Endometrioid 9 (2.0%) 45 (10.2%) 16 (3.6%) 38 (8.6%)
 CCC 23 (5.2%) 21 (4.8%) 25 (5.7%) 19 (4.3%)
 LGSC 1 (0.2%) 17 (3.9%) 4 (0.9%) 14 (3.2%)
 SBOT 0 (0.0%) 10 (2.3%) 0 (0.0%) 10(2.3%)
Grade
 1 4 (0.9%) 29 (6.6%) 0.813 7 (1.6%) 26 (5.9%) 0.174
 2 9 (2.0%) 56 (12.7%) 11 (2.5%) 54 (12.2%)
 3 54 (12.2%) 289 (65.5%) 94 (21.3%) 249 (56.5%)
Stage
 I 36 (8.3%) 123 (28.3%) 0.013* 50 (11.5%) 109 (25.1%) 0.209
 II 6 (1.4%) 43 (9.9%) 12 (2.8%) 37 (8.5%)
 III 20 (4.6%) 175 (40.3%) 42 (9.7%) 153 (35.3%)
 IV 5 (1.2%) 26 (6.0%) 8 (1.8%) 23 (5.3%)
Residual disease
 No residual tumour 44 (11.3%) 195 (50.0%) 0.227 72 (18.5%) 167 (42.8%) 0.076
 Residual tumour (< 2 cm) 5 (1.3%) 41 (10.5%) 10 (2.6%) 36 (9.2%)
 Residual tumour (> 2 cm) 13 (3.3%) 92 (23.6%) 20 (5.1%) 85 (21.8%)
Response to platinum-based chemotherapy
 Chemo-refractory 6 (2.1%) 24 (8.5%) 0.589* 13 (4.6%) 17 (6.0%) 0.154
 Chemo-resistance 2 (0.7%) 19 (6.7%) 6 (2.1%) 15 (5.3%)
 Chemo-sensitivity 35 (12.4%) 196 (69.5%) 61 (21.6%) 170 (60.3%)
Response to taxane-containing (i.e., paclitaxel, docetaxel) chemotherapy regimens
 Chemo-resistance 3 (2.5%) 18 (14.8%) 0.774* 11 (9.0%) 10 (8.2%) 0.006
 Chemo-sensitivity 17 (13.9%) 84 (68.9%) 23 (18.9%) 78 (63.9%)
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Correlations between calpain family expression 
and calpain‑associated protein expression
Correlations between Syk and MAP-4 expression with cal-
pain system proteins (i.e., calpain-1, -2, -4 and calpastatin) 
were studied in the whole cohort. The correlation strength 
between calpain-2 expression and Syk and MAP4 expres-
sion are considered too weak to be meaningful (rs < 0.16). 
Nevertheless, MAP4 expression was moderately correlated 
with calpain-1 (rs = 0.537, P < 0.001) (Table 4); in addition, 
Syk-c and Syk-n expression were strongly associated with 
each other (rs = 0.809, P < 0.001) (Table 4).
The correlations were also studied in each histological 
subtype separately (data not shown). The moderate cor-
relation between calpain-1 and MAP4 was also observed 
in HGSCs (rs = 0.472, P < 0.001, n = 255) and CCCs 
(rs = 0.516, P < 0.001, n = 42), whilst strong correlation 
was observed in endometrioid (rs = 0.687, P < 0.001, n = 50) 
and mucinous tumours (rs = 0.708, P < 0.001, n = 36), with 
no significant correlation detected between calpain-1 and 
MAP4 in LGSC. For calpain-1 and Syk expression, a weak 
correlation was found in the whole cohort and also in HGSCs 
(Syk-c: rs = 0.347, P < 0.001, n = 257; Syk-n: rs = 0.313, 
P < 0.001, n = 257) and CCCs (Syk-c: rs = 0.378, P = 0.014, 
n = 42; Syk-n: rs = 0.327, P = 0.035, n = 42), whilst a mod-
erate correlation was found in mucinous tumours (Syk-c: 
rs = 0.425, P = 0.007, n = 39; Syk-n: rs = 0.471, P = 0.002, 
n = 39), no correlation was detected between calpain-1 
and Syk expression in LGSCs or endometrioid tumours. 
Either no correlation or weak correlation was detected 
between Syk-n and MAP4 expression in the whole cohort 
and in the five groups of histological subtypes (data not 
shown). Between Syk-c and MAP4 expression, a weak cor-
relation was found in the whole cohort and also in HGSCs 
(rs = 0.312, P < 0.001, n = 265) and mucinous tumours 
(rs = 0.376, P = 0.018, n = 39), whilst a moderate correla-
tion was found in CCCs (rs = 0.576, P < 0.001, n = 44); no 
correlation was detected between Syk and MAP4 expression 
in LGSCs or endometrioid tumours (data not shown). It is 
noticeable that CXCR3 and Syk expression lacked correla-
tion or was weakly correlated in the whole cohort and 4 of 
the histological subtypes; only in LGSC type, strong cor-
relation was detected (Syk-c: rs = 0.640, P = 0.006, n = 17; 
Syk-n: rs = 0.606, P = 0.010, n = 17). Findings suggest that 
the role this panel of proteins played and how they cooper-
ated with each other may be histological subtype dependent.
Additional survival analysis was conducted by recat-
egorised tumours according to expression of any two of 
MAP4, Syk-c, Syk-n, calpain-1, -2, -4 and calpastatin into 
four groups each time; for example, grouping patients into 
the following four groups (i.e., high Syk-n and high Syk-c; 
high Syk-n and low Syk-c; low Syk-n and high Syk-c; low 
Syk-n and low Syk-c). On the survival analysis, the P values 
from the log-rank test obtained with recategorised groups 
were less significant than those obtained with single marker 
(Table S3).
Discussion
Among the ovarian cancer histological subtypes, HGSCs 
displayed higher expression of Syk-c and -n (Syk-c: 
χ2 = 58.835, df = 5, P = 2.115E−11 and Syk-n: χ2 = 29.874, 
Table 3  Association between MAP4 expression and clinicopathologi-
cal criteria
HGSC high-grade serous carcinoma, LGSC low-grade serous car-
cinoma, CCC clear-cell carcinoma, SBOT serous borderline ovarian 
tumour
*Expected count less than 5. Significant P values are indicated by 
bold type
Variable MAP4
Low High P value
Age
 ≤ 62 82 (18.6%) 136 (30.8%) 0.169
 > 62 70 (15.9%) 153 (34.7%)
Histological subtypes
 HGSC 59 (13.3%) 211 (47.7%) 6.7681E−11
 Mucinous 25 (5.7%) 16 (3.6%)
 Endometrioid 22 (5.0%) 33 (7.5%)
 CCC 29 (6.6%) 16 (3.6%)
 LGSC 11 (2.5%) 8 (1.8%)
 SBOT 6 (1.4%) 6 (1.4%)
Grade
 1 16 (3.6%) 19 (4.3%) 0.00001
 2 38 (8.6%) 28 (6.3%)
 3 97 (22.0%) 243 (55.1%)
Stage
 I 75 (17.2%) 89 (20.5%) 0.001
 II 12 (2.8%) 36 (8.3%)
 III 52 (12.0%) 140 (32.2%)
 IV 10 (2.3%) 21 (4.8%)
Residual disease
 No residual tumour 97 (24.8%) 144 (36.8%) 0.005
 Residual tumour (< 2 cm) 10 (2.6%) 38 (9.7%)
 Residual tumour (> 2 cm) 27 (6.9%) 75 (19.2%)
Response to platinum-based chemotherapy
 Chemo-refractory 8 (2.8%) 22 (7.8%) 0.509
 Chemo-resistance 8 (2.8%) 11 (3.9%)
 Chemo-sensitivity 72 (25.5%) 161 (57.1%)
Response to taxane-containing (i.e., paclitaxel, docetaxel) chemo-
therapy regimens
 Chemo-resistance 9 (7.5%) 10 (8.3%) 0.072
 Chemo-sensitive 27 (22.5%) 74 (61.7%)
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df = 5, P = 0.000016, respectively). In addition, the present 
study indicated that low Syk-c expression was associated 
with lower tumour stage (χ2 = 10.725, df = 3, P = 0.013). In 
light of such data, it is likely that Syk may promote tumour 
spread via increasing cell invasion and migration at the 
early stage of ovarian carcinogenesis. Consistently, high 
Syk expression (mRNA level, n = 45; protein level, n = 38) 
significantly correlated with worse survival, enhanced cell 
migration and metastases to the lymph nodes in patients with 
squamous cell carcinomas of the head and neck (Luangdilok 
et al. 2007). Other pro-survival functions of Syk include 
anti-apoptosis (Geahlen 2014; Krisenko and Geahlen 2015), 
cancer cell growth and survival (Prinos et al. 2011; Udyavar 
et al. 2013; Fei et al. 2013), migration and dissemination 
(Luangdilok et al. 2007; Ghotra et al. 2015; Katz et al. 2005; 
Krisenko and Geahlen 2015). Yet, other studies suggest that 
Syk is absent from many highly aggressive epithelial cell-
derived tumours (Krisenko and Geahlen 2015; Coopman 
and Mueller 2006) and Syk may increase cell–cell interac-
tions and limit EMT (Krisenko and Geahlen 2015). To be 
specific, Syk knockdown in more well-differentiated can-
cers was found to enhance invasive/anchorage-independent 
growth and motility (Fei et al. 2013) whilst its re-introduc-
tion in more malignant, invasive cancer cells decreased can-
cer malignancy through increasing adhesion and reducing 
tumour cell growth, motility, invasion and metastasis (Ogane 
et al. 2009; Fei et al. 2013; Peng et al. 2013; Krisenko and 
Geahlen 2015). The invasion suppressive function of full-
length Syk has been reported to correlate with Syk nuclear 
localisation suggesting that Syk-n possesses biological 
activities associated with tumour suppression in mammary 
epithelial cells (Wang et al. 2003).
Fig. 2  Kaplan–Meier survival curves show the impact of Syk-c, 
Syk-n and MAP4 expression on overall survival and progression-
free survival. There were no differences in survival between patients 
with tumours expressing high MAP4 or Syk and those with tumours 
expressing low MAP4 or Syk. Significance was determined using the 
log-rank test. The tables shown below the Kaplan–Meier survival 
curves listed the number of patients at risk at the specific months. 
High expression—black line, low expression—grey line
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Fig. 3  Kaplan–Meier survival curves show the impact of Syk expres-
sion on overall survival in different subgroups. Survival analysis 
shows that high Syk-n expression significantly associated with bet-
ter (P = 0.010) overall survival for ovarian cancer patients resistant 
to platinum-based chemotherapy (a), patients with tumour confined 
to the ovaries (b) and patients with no residual carcinoma (c). Sig-
nificance was determined using the log-rank test. The tables shown 
below the Kaplan–Meier survival curves listed the number of patients 
at risk at the specific months. High expression—black line, low 
expression—grey line
Table 4  Spearman’s rank correlation coefficient between defined proteins of interest (469 valid cases)
*Correlation is significant at the 0.01 level (two-tailed)
Significant P values are indicated by bold font
rs Spearman’s correlation coefficient, Syk-n nuclear Syk, Syk-c cytoplasmic Syk
Calpastatin Calpain-1 Calpain-2 Calpain-4
Syk-c
 rs 0.135* 0.396* 0.127* 0.145*
 Sig. 0.006 4.3041E−17 0.010 0.003
 N 415 416 415 416
Syk-n
 rs 0.160* 0.346* 0.082 0.129*
 Sig. 0.001 4.0912E−13 0.097 0.009
 N 415 416 415 416
MAP4
 rs 0.244* 0.537* 0143* 0.286*
 Sig. 4.8817E−7 2.3144E−32 0.004 2.8108E−9
 N 414 415 414 415
Syk-c Syk-n
MAP4
 rs 0.385* 0.290*
 Sig. 1.350E−16 (n = 429) 9.765E−10 (n = 429)
Syk-c
 rs – 0.809*
 Sig. – 3.189E−103 (n = 441)
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In the current study, a tumour-suppressive effect of 
Syk-n was reflected in its negative association with chemo-
resistance in patients treated by therapy containing taxane 
(χ2 = 7.582, df = 1, P = 0.006) and positive association with 
overall survival when patients had tumours confined to the 
ovaries (stage 1 ovarian cancer) (P = 0.001), in the subgroup 
of platinum-resistant patients (P = 0.001) and in the group of 
patients with no residual disease (P = 0.001). Current find-
ings are in contrast to those from a previous study conducted 
in ovarian cancer cells where Syk expression/activity lev-
els positively associated with cell resistance to paclitaxel; 
moreover, in the same study, pharmacological and genomic 
Syk inhibitors had a synergistic effect with paclitaxel both 
in vitro and in vivo especially in cells that were resistant to 
paclitaxel (Yu et al. 2015). A separate study showed that 
Syk was preferentially expressed in recurrent HGSCs after 
chemo-therapeutic treatment in comparison with the primary 
tumours from the same patients (Jinawath et al. 2010). More-
over, restriction of Syk to the nucleus has been suggested to 
diminish stress-induced activation of caspase 3 in B cells 
(Zhou et al. 2006; Mohammad et al. 2016) and tumour cells 
(Wang et al. 2005).
The discrepancy between the above and the strong and 
positive correlation between Syk-c and -n expression in the 
current study (rs = 0.809, P < 0.001) may be due to the dif-
ferent splice variants of Syk and their localisation. Although 
Syk(L) and Syk(S) cannot be discriminated via IHC with 
the antibody used in the current study, which targets amino 
acids 313–339, Syk-n and Syk-c were studied separately. 
Full-length Syk is known as Syk long isoform, Syk(L), 
whilst the shorter gene product Syk(S) omits a stretch of 23 
amino acids (AA283–305) in linker B (Grädler et al. 2013; 
Krisenko and Geahlen 2015). Syk(L) and Syk(S) were found 
in both nucleus and cytoplasm (Wang et al. 2003; Zhou 
et al. 2006; Luangdilok et al. 2007) with Syk(L) predomi-
nantly presenting in the nucleus and Syk(S) in cytoplasm 
in untreated tumour cells (Prinos et al. 2011; Wang et al. 
2005). A Syk splicing pattern was linked to ovarian but not 
breast cancer (Klinck et al. 2008; Venables et al. 2008; Pri-
nos et al. 2011) and SKOV3 cells reportedly preferentially 
express Syk(L) (Prinos et al. 2011). Further investigation 
is needed to understand the contradictory functions of Syk 
in terms of cellular context and tumour microenvironment.
In the current study, a significant association was detected 
between high MAP4 expression and the presence of resid-
ual tumour (χ2 = 10.426, df = 2, P = 0.005). Low MAP4 
expression was significantly associated with lower stage 
(χ2 = 15.857, df = 3, P = 0.001) which agreed with a study 
of esophageal squamous cell carcinomas (n = 364), where 
MAP4 expression was linked with tumour stage and lymph 
node metastasis (Jiang et al. 2016). In addition, the knock-
down of MAP4 was found able to markedly inhibit blad-
der cancer cells invasion (Ou et al. 2014). In addition, in 
the present study, low MAP4 expression was significantly 
associated with lower grade (χ2 = 22.933, df = 2, P < 0.001) 
which has also been observed in bladder cancer (n = 34) 
(Ou et al. 2014). Although a higher level of MAP4 mRNA 
was found in non-small cell lung carcinomas when com-
pared to normal lung tissues (Cucchiarelli et al. 2008) and 
MAP4 expression was associated with shorter survival of 
the esophageal squamous cell carcinoma patients (n = 364) 
(Jiang et al. 2016), no significant association was detected 
in the present study between MAP4 expression and overall 
survival in either the whole cohort or any of the subgroups 
tested.
An association between MAP4 and paclitaxel resistance 
has been observed in different cancer types including ovar-
ian cancer (Poruchynsky et al. 2001; Orr et al. 2003; Aoki 
et al. 2009). In the chemotherapy-naïve cases of the current 
study, the correlation between high MAP4 expression and 
chemo-sensitisation was statistically significant in patients 
treated by taxane-containing chemotherapy (χ2 = 4.596, 
df = 1, P = 0.032). As an anti-tumour drug, taxane induces 
microtubule stabilisation and reduces microtubule dynam-
ics which promotes mitotic arrest and cell death (Aoki 
et al. 2009). Based on the mechanism of taxane on tumour 
cells, proteins that are involved in the regulation of cellular 
microtubule dynamics via interacting with tubulin dimers or 
polymerised microtubules clearly possess the potential for 
modulating the cell sensitivity towards paclitaxel (Orr et al. 
2003). The drug sensitivity profile of ovarian cancer pacli-
taxel-resistant sublines parallels the regulation of MAP4 
modification: MAP4 phosphorylation and dissociation from 
microtubules decrease the sensitivity of paclitaxel-resistant 
ovarian cell lines towards paclitaxel (Poruchynsky et al. 
2001; Orr et al. 2003). However, down-regulation of MAP4 
in SKOV3 cells did not influence the sensitivity to either 
paclitaxel or cisplatin; and MAP4 status was not correlated 
with the survival of patients treated with either taxane-based 
regimen or taxane-free regimen (Aoki et al. 2009). The pre-
cise role for MAP4 in tumour sensitivity to taxanes remains 
to be defined.
As indicated above, results from previous ovarian can-
cer studies confirm that calpain-2 is an important factor 
in cancer survival (Storr et al. 2012; Zhang et al. 2018). 
In addition, calpain-4 and calpastatin were also associated 
with patient overall survival (Zhang et al. 2018). Such previ-
ous studies focused on protein expression and thus cannot 
directly reflect the actual enzyme activity level of the cal-
pain system. How the calpain system is involved in patient 
outcomes remains unclear. With low calpain-1 expres-
sion associating with stage 1 tumour (Zhang et al. 2018), 
in the current study, low Syk-c and MAP4 expression also 
related to organ-confined status (Syk-c: χ2 = 9.975, df = 1, 
P = 0.002; and MAP4: χ2 = 15.402, df = 1, P = 0.000087) 
(Tables 2, 3). Thus, the calpain system, together with Syk-c 
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and MAP4, might be linked with overall survival via their 
associations with tumour spread. Currently, there is a lack 
of supporting information to explain the positive correla-
tions between calpain-1 and Syk/MAP4 (MAP4 and cal-
pain-1: rs = 0.537, P = 2.3144E−32; Syk-c and calpain-1: 
rs = 0.396, P = 4.3041E−17; MAP4 and Syk-c: rs = 0.385, 
P = 1.350E−16) (Table 4). In vitro studies focusing on the 
activity of these proteins and ovarian cancer cell invasion 
might shed more light on whether, and how, the calpain sys-
tem interacts with Syk/MAP4 to influence patient outcome.
In conclusion, both MAP4 and Syk were associated with 
tumour stage. The current study also observed the paradoxi-
cal roles of Syk. High Syk-n expression indicated a better 
overall survival in certain subgroups of patients. Low Syk-n 
expression significantly associated with chemo-resistance in 
patients treated by therapy containing taxane which support 
the role of Syk as a tumour suppressor. Contradictory, low 
Syk-c expression was associated with low stage. Together, 
it appears from this study of ovarian cancers that high Syk 
expression may facilitate tumour spreading (higher stage) 
whilst high Syk-n sensitises tumour cells to taxane-contain-
ing chemotherapy. Significant correlations between MAP4, 
Syk, and calpain-1 suggest that calpain, Syk and MAP4 
might be interrelated and interact on each other to modu-
late cancer cell spread. How MAP4, Syk and calpain-1 are 
involved in tumour cell spreading/migration, and in cellular 
response to taxane-containing chemotherapy, remains to be 
elucidated.
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